JOHN C. REED - 17 Oct 2025 Form 4 Insider Report for JOHNSON & JOHNSON (JNJ)

Signature
/s/ Laura H. McFalls, as attorney-in-fact for John C. Reed
Issuer symbol
JNJ
Transactions as of
17 Oct 2025
Net transactions value
-$4,185,793
Form type
4
Filing time
20 Oct 2025, 19:13:56 UTC
Previous filing
18 Jul 2025
Next filing
18 Feb 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
REED JOHN C EVP, Innovative Medicine, R&D ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK /s/ Laura H. McFalls, as attorney-in-fact for John C. Reed 20 Oct 2025 0001181561

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JNJ Common Stock Options Exercise $3,430,180 +21,721 +204% $157.92 32,379 17 Oct 2025 Direct
transaction JNJ Common Stock Sale $4,185,793 -21,721 -67% $192.71 10,658 17 Oct 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JNJ Employee Stock Options (Right to Buy) Options Exercise $3,430,180 -21,721 -33% $157.92 43,442 17 Oct 2025 Common Stock 21,721 $157.92 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades at prices ranging from $192.69 to $192.87. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2 Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests in three equal annual installments beginning on the first anniversary of the grant date.